Last reviewed · How we verify
NCT03907774
MPN Podcast Pilot Study
trial in Myeloproliferative Neoplasm, Unclassifiable in 39 participants. Completed in 24 November 2019.
24 November 2019
Quick facts
| Lead sponsor | Arizona State University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 39 |
| Start date | 1 June 2019 |
| Primary completion | 24 November 2019 |
| Estimated completion | 24 November 2019 |
| Sites | 1 location across United States |
Conditions studied
- Myeloproliferative Neoplasm, Unclassifiable — all drugs for Myeloproliferative Neoplasm, Unclassifiable →
Sponsor
Arizona State University
Who can join
18 and older, any sex, with Myeloproliferative Neoplasm, Unclassifiable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Enrolled MPN patients will participate in a podcast intervention via a smartphone app. They will listen to 60 minutes per week of podcasts through this app, which consist of cancer-related health education material. Participants have the option to listen to additional podcasts beyond the 60-minute weekly prescription if they desire. Participation will be tracked through self-report logs. In addition, questionnaires will be administered at baseline, midpoint (week 6), and post-intervention (week 12), which ask about demographics, health information, and satisfaction. The hypothesis is that the smartphone app is feasible for delivering home-based health education podcasts to MPN patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Novel Educational Control Group Mobile App for Meditation Interventions: Single-Group Feasibility Trial.
Huberty J, Eckert R, Puzia M, Laird B, et al · · 2020 · cited 10× · PMID 32706719 · DOI 10.2196/19364
Verify or expand the search:
- PubMed search for NCT03907774
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myeloproliferative Neoplasm, Unclassifiable
Currently open trials in the same condition.
- NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
- NCT03862157 — Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia · Phase 1, PHASE2 · active not recruiting
Other Arizona State University trials
Trials by the same sponsor.
- NCT07519408 — Acute Kidney Injury and Ultra-endurance Running · NA · not yet recruiting
- NCT05784467 — Methamphetamine, PrEP, and Intersectional Stigma Study · NA · not yet recruiting
- NCT07375043 — Drumming Groups for Parents of Autistic Children · NA · not yet recruiting
- NCT07297901 — App-based Breathing Program for Migraine Relief · NA · enrolling by invitation
- NCT06721793 — The Impact of a Caffeinated Sports Drink on Performance · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03907774 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arizona State University
- Last refreshed: 27 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03907774.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing